The group, known as MESO, has listed its headquarters at 4008 N.E. Martin Luther King Jr. Blvd. and 4003-4009 N.E. Grand Ave. for about $1.7 million.

This is the target market for Ryoncil. Meso’s second product is Revascor (rexlemestrocel-L), which, as I noted many times before, was something of a trouble for the company, having failed ...

Teva Pharmaceutical Industries Ltd. ADR-0.46% $24.97B ...

RVPH Reviva Pharmaceuticals Holdings, Inc.

After hours: January 17 at 7:31:23 p.m. EST ...